Serbian gov't signs MoU with pharmaceuticals company MSD

BELGRADE - Serbian PM Ana Brnabic and the senior vice president of the pharmaceuticals firm Merck Sharp and Dohme (MSD), Cyril Schiever, signed on Wednesday a MoU that will be significant for Serbia's future BIO4 Campus research centre.

Brnabic thanked MSD for supporting "our efforts to make Serbia a leader in biotechnology, biomedicine, bioresearch and bioinformatics."

She said the MoU dealt with MSD's participation in the BIO4 Campus project.

"It is an extremely significant reference that will help us to also bring other major biopharmaceuticals companies and research and development institutes to the BIO4 Campus - whose construction will begin by the end of the year - in the weeks and months to come and together make a centre for future research in those fields for this part of Europe," Brnabic said.

"Our ambition is to make it one of the most significant centres in Europe," Brnabic said, adding that this was an important day for the campus and for Serbia as a major biotech research and development destination.